Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Tracking Information
First Submitted Date	May 20, 2008
First Posted Date	May 21, 2008
Last Update Posted Date	January 24, 2011
Study Start Date	May 2007
Primary Completion Date	Not Provided
Current Primary Outcome Measures; (submitted: May 20, 2008)	Evaluate Faslodex therapeutic strategy and treatment duration [ Time Frame: At the end of the study ]; Describe the characteristics of patients treated with Faslodex [ Time Frame: At the end of the study ]
Original Primary Outcome Measures	Same as current
Change History	Complete list of historical versions of study NCT00681369 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures	Not Provided
Original Secondary Outcome Measures	Not Provided
Current Other Outcome Measures	Not Provided
Original Other Outcome Measures	Not Provided
Descriptive Information
Brief Title	Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
Official Title	Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
Brief Summary	the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Detailed Description	Not Provided
Study Type	Observational
Study Design	Observational Model: Cohort; Time Perspective: Retrospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Probability Sample
Study Population	Hospital sample
Condition	Breast Cancer
Intervention	Not Provided
Study Groups/Cohorts	1; Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status	Completed
Actual Enrollment; (submitted: May 20, 2008)	217
Original Actual Enrollment	Same as current
Actual Study Completion Date	June 2007
Primary Completion Date	Not Provided
Eligibility Criteria	Inclusion Criteria: Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Sex/Gender	Sexes Eligible for Study: Female
Ages	Child, Adult, Senior
Accepts Healthy Volunteers	No
Contacts	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries	Not Provided
Removed Location Countries
Administrative Information
NCT Number	NCT00681369
Other Study ID Numbers	NIS-OFR-FAS-2007/1
Has Data Monitoring Committee	No
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Francisco Sapunar - Medical Science Director, AstraZeneca
Study Sponsor	AstraZeneca
Collaborators	Not Provided
Investigators	Principal Investigator: Alain FLINOIS TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge
PRS Account	AstraZeneca
Verification Date	January 2011